^
    Evidence Level:
    Resistant: C4 – Case Studies

    [KIF5B-RET fusion + TP53 H193R + MYC amplification-Lung Adenocarcinoma-pralsetinib]

    Source:
    IASLC-WCLC 2022
    Test:

    Idylla™ GeneFusion Assay

    Title:
    EP08.02-037 - Small Cell Transformation in a Patient with RET Fusion Positive Lung Adenocarcinoma on Pralsetinib.
    Published date:
    07/12/2022
    Excerpt:
    A 72-year-old never smoker male patient was diagnosed with lung adenocarcinoma...Molecular workup (MCSTP) identified a KIF5B::RET fusion along with a loss-of-function mutation in TP53 (H193R) and MYC amplification….Pralsetinib was resumed following completion of radiation therapy, however further progression was detected 2 months later in the chest, abdomen and brain with fistula formation between the right mainstem bronchus and the subcarinal lymph node block.